# A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

> **NCT03449147** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1317 (actual)

## Conditions studied

- Chronic Cough

## Interventions

- **DRUG:** Placebo
- **DRUG:** Gefapixant 15 mg BID
- **DRUG:** Gefapixant 45 mg BID

## Key facts

- **NCT ID:** NCT03449147
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-15
- **Primary completion:** 2020-08-20
- **Final completion:** 2020-10-30
- **Target enrollment:** 1317 (ACTUAL)
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03449147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03449147, "A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03449147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*